Skip to main content
Anixa Biosciences Inc logo

Anixa Biosciences Inc — Investor Relations & Filings

Ticker · ANIX ISIN · US45069V2034 LEI · 549300PW2C2QTAJL2D19 US Professional, scientific and technical activities
Open in API
Filings indexed 958 across all filing types
Latest filing 2021-06-02 Director's Dealing
Country US United States of America
Listing US ANIX

About Anixa Biosciences Inc

https://www.anixa.com/

Anixa Biosciences Inc. is a clinical-stage biotechnology company focused on developing therapies and vaccines for the treatment and prevention of cancer. The company's portfolio is centered on two main platforms: a therapeutics program and a vaccine program. The therapeutics portfolio features a Chimeric Antigen Receptor T-cell (CAR-T) immunotherapy, which genetically engineers a patient's own immune cells to target and destroy solid tumors. The vaccine portfolio includes preventative and therapeutic candidates for various cancers, with a primary focus on breast and ovarian cancer, and discovery programs for lung, colon, and prostate cancer. Anixa aims to address critical unmet needs in oncology through these innovative approaches.

Recent filings

Filing Released Lang Actions
Director's Dealing 2021
Director's Dealing
2021-06-02 English
Director's Dealing 2021
Director's Dealing
2021-06-02 English
Director's Dealing 2021
Director's Dealing
2021-06-02 English
Director's Dealing 2021
Director's Dealing
2021-06-02 English
Director's Dealing 2021
Director's Dealing
2021-06-02 English
Declaration of Voting Results & Voting Rights Announcements 2021
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 21, 2021, reporting the results of the 2021 annual meeting of stockholders of Anixa Biosciences, Inc. It details the voting results on various proposals including election of directors, executive compensation approval, ratification of the independent auditor, and amendments to the Certificate of Incorporation. The key content is the submission of matters to a vote of security holders, which corresponds to official results from shareholder votes at a general meeting. The document also references a corporate presentation used at the meeting but does not contain the presentation itself or detailed financial data. The primary focus is on voting results, which fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length (8176 characters) is sufficient to contain detailed voting results, not just an announcement of a report. Therefore, the correct classification is DVA with high confidence.
2021-05-27 English

Browse filings by year

32 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.